Jinhe Biotech announced that in the first half of 2026, it achieved operating income of 1,448 billion yuan, a year-on-year increase of 4.13%; net profit attributable to shareholders of listed companies was 131 million yuan, a year-on-year decrease of 5.09%; after deducting non-net profit of 126 million yuan, a year-on-year decrease of 1.85%. During the reporting period, no cash dividends will be paid, bonus shares will not be given, and capital will not be transferred from the Provident Fund. On March 26, 2026, the company completed the repurchase and cancellation of 2.13 million restricted shares; on July 16, 7.946,400 shares of the company's shares were transferred untraded to a special account for the 2026 Employee Stock Ownership Plan.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.